Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952775 | 1.00 | ERN1 (0.64) | ERN1PTGS1PTGS2ALOX5 | |
| SCHEMBL28686976 | 0.84 | ERN1 (0.78) | ERN1 | |
| SCHEMBL19781757 | 0.79 | PTGS1 (0.47) | ERN1PTGS1PTGS2ALOX5 | |
| SCHEMBL29957335 | 0.78 | ERN1 (0.78) | ERN1PTGS1PTGS2ALOX5 | |
| SCHEMBL2788053 | 0.78 | ERN1 (0.78) | ERN1PTGS1PTGS2ALOX5 | |
| SCHEMBL29740541 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL12697428 | 0.78 | ERN1 (0.76) | ERN1 | |
| SCHEMBL19682793 | 0.78 | ERN1 (0.47) | ERN1PTGS1PTGS2 | |
| SCHEMBL29957419 | 0.78 | ERN1 (0.47) | ERN1PTGS1PTGS2 | |
| SCHEMBL14877143 | 0.78 | ERN1 (0.47) | ERN1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903239-B2 | Fluorinated benzaldehydes | BAYER CHEMICAL AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | claimed |
| US-20040133043-A1 | Fluorinated benzaldehydes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | claimed |
| EP-1428814-A1 | Fluorine containing benzaldehydes | Bayer Chemicals AG (DE) | 2004-06-16 | — | — | EP | claimed |
| EP-4703358-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | China Pharmaceutical University (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | DIGMBIO, Inc. (KR) | 2025-11-04 | — | — | US | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024222918-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | 中国药科大学 | 2024-10-31 | — | — | WO | disclosed |
| US-20240360124-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-101203500-A | Substituted arylamine compounds and their use as 5-HT6Use of modulators | EPIX DELAWARE INC (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-6903239-B2 | Fluorinated benzaldehydes | BAYER CHEMICAL AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | disclosed |
| US-20040133043-A1 | Fluorinated benzaldehydes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| JP-2004189741-A | METHOD FOR PRODUCING FLUORINATED BENZALDEHYDE, THE COMPOUND AND INTERMEDIATE PRODUCT FOR THE SAME IN PROCESS FOR PRODUCING THE SAME | BAYER CHEMICALS AG | 2004-07-08 | — | — | JP | disclosed |
| CN-1506347-A | Fluoridized benzaldehyde | ˹���ػ�ѧ��Ʒ�ɷ�����˾ | 2004-06-23 | — | — | CN | disclosed |
| EP-1428814-A1 | Fluorine containing benzaldehydes | Bayer Chemicals AG (DE) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | PARP1, PARP2, PARP11 | ERN1 1170/4885PTGS1 135/4885PTGS2 266/4885 |
| US-20040133043-A1 | Fluorinated benzaldehydes | PFAS, FIP1L1, AFF2 | ERN1 4585/4885PTGS1 1899/4885PTGS2 1477/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | ERN1 3692/4885PTGS1 93/4885PTGS2 175/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ERN1 4404/4885PTGS1 1963/4885PTGS2 1234/4885 |
| US-20240360124-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | ERN1 1120/4885PTGS1 1385/4885PTGS2 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.